| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | ATP-dependent chromatin remodeler activity | 9.00e-09 | 37 | 83 | 6 | GO:0140658 | |
| GeneOntologyMolecularFunction | granulocyte colony-stimulating factor receptor binding | 2.69e-07 | 14 | 83 | 4 | GO:0005130 | |
| GeneOntologyMolecularFunction | GPI anchor binding | 2.31e-06 | 23 | 83 | 4 | GO:0034235 | |
| GeneOntologyMolecularFunction | filamin binding | 6.09e-06 | 29 | 83 | 4 | GO:0031005 | |
| GeneOntologyMolecularFunction | Toll-like receptor binding | 6.09e-06 | 29 | 83 | 4 | GO:0035325 | |
| GeneOntologyMolecularFunction | bile acid transmembrane transporter activity | 1.17e-05 | 34 | 83 | 4 | GO:0015125 | |
| GeneOntologyMolecularFunction | catalytic activity, acting on DNA | 1.33e-05 | 262 | 83 | 8 | GO:0140097 | |
| GeneOntologyMolecularFunction | ATP-dependent activity, acting on DNA | 1.49e-05 | 127 | 83 | 6 | GO:0008094 | |
| GeneOntologyMolecularFunction | protein tyrosine kinase binding | 3.67e-05 | 149 | 83 | 6 | GO:1990782 | |
| GeneOntologyMolecularFunction | phosphatidylinositol binding | 5.07e-05 | 316 | 83 | 8 | GO:0035091 | |
| GeneOntologyMolecularFunction | helicase activity | 5.10e-05 | 158 | 83 | 6 | GO:0004386 | |
| GeneOntologyMolecularFunction | glycolipid binding | 5.10e-05 | 49 | 83 | 4 | GO:0051861 | |
| GeneOntologyMolecularFunction | histone binding | 1.18e-04 | 265 | 83 | 7 | GO:0042393 | |
| GeneOntologyMolecularFunction | lipid transporter activity | 1.67e-04 | 196 | 83 | 6 | GO:0005319 | |
| GeneOntologyMolecularFunction | organic hydroxy compound transmembrane transporter activity | 2.07e-04 | 70 | 83 | 4 | GO:1901618 | |
| GeneOntologyMolecularFunction | lipid transmembrane transporter activity | 2.43e-04 | 73 | 83 | 4 | GO:0170055 | |
| GeneOntologyMolecularFunction | monocarboxylic acid transmembrane transporter activity | 5.40e-04 | 90 | 83 | 4 | GO:0008028 | |
| GeneOntologyMolecularFunction | catalytic activity, acting on a nucleic acid | 1.42e-03 | 645 | 83 | 9 | GO:0140640 | |
| GeneOntologyMolecularFunction | carbohydrate binding | 1.85e-03 | 310 | 83 | 6 | GO:0030246 | |
| GeneOntologyMolecularFunction | phospholipid binding | 1.99e-03 | 548 | 83 | 8 | GO:0005543 | |
| GeneOntologyMolecularFunction | ATP hydrolysis activity | 2.40e-03 | 441 | 83 | 7 | GO:0016887 | |
| GeneOntologyMolecularFunction | minus-end-directed microtubule motor activity | 2.50e-03 | 18 | 83 | 2 | GO:0008569 | |
| GeneOntologyMolecularFunction | lipid binding | NPC1 CD6 OSBPL2 IQGAP2 PSG1 PSG3 P2RX2 PSG9 INPPL1 APOL6 PSG8 | 2.54e-03 | 988 | 83 | 11 | GO:0008289 |
| GeneOntologyMolecularFunction | calmodulin binding | 2.72e-03 | 230 | 83 | 5 | GO:0005516 | |
| GeneOntologyMolecularFunction | hydrolase activity, acting on glycosyl bonds | 3.07e-03 | 144 | 83 | 4 | GO:0016798 | |
| GeneOntologyMolecularFunction | ATP-dependent activity | 3.98e-03 | 614 | 83 | 8 | GO:0140657 | |
| GeneOntologyBiologicalProcess | negative regulation of brown fat cell proliferation | 2.48e-07 | 14 | 84 | 4 | GO:0070348 | |
| GeneOntologyBiologicalProcess | regulation of brown fat cell proliferation | 3.38e-07 | 15 | 84 | 4 | GO:0070347 | |
| GeneOntologyBiologicalProcess | positive regulation of homophilic cell adhesion | 3.38e-07 | 15 | 84 | 4 | GO:1903387 | |
| GeneOntologyBiologicalProcess | negative regulation of natural killer cell mediated immune response to tumor cell | 3.38e-07 | 15 | 84 | 4 | GO:0002856 | |
| GeneOntologyBiologicalProcess | negative regulation of natural killer cell mediated cytotoxicity directed against tumor cell target | 3.38e-07 | 15 | 84 | 4 | GO:0002859 | |
| GeneOntologyBiologicalProcess | insulin receptor internalization | 4.49e-07 | 16 | 84 | 4 | GO:0038016 | |
| GeneOntologyBiologicalProcess | brown fat cell proliferation | 5.85e-07 | 17 | 84 | 4 | GO:0070342 | |
| GeneOntologyBiologicalProcess | insulin catabolic process | 5.85e-07 | 17 | 84 | 4 | GO:1901143 | |
| GeneOntologyBiologicalProcess | granulocyte colony-stimulating factor signaling pathway | 5.85e-07 | 17 | 84 | 4 | GO:0038158 | |
| GeneOntologyBiologicalProcess | regulation of homophilic cell adhesion | 7.50e-07 | 18 | 84 | 4 | GO:1903385 | |
| GeneOntologyBiologicalProcess | negative regulation of hepatocyte proliferation | 1.18e-06 | 20 | 84 | 4 | GO:2000346 | |
| GeneOntologyBiologicalProcess | negative regulation of fat cell proliferation | 1.45e-06 | 21 | 84 | 4 | GO:0070345 | |
| GeneOntologyBiologicalProcess | negative regulation of response to tumor cell | 1.45e-06 | 21 | 84 | 4 | GO:0002835 | |
| GeneOntologyBiologicalProcess | negative regulation of immune response to tumor cell | 1.45e-06 | 21 | 84 | 4 | GO:0002838 | |
| GeneOntologyBiologicalProcess | blood vessel remodeling | 1.48e-06 | 87 | 84 | 6 | GO:0001974 | |
| GeneOntologyBiologicalProcess | negative regulation of granulocyte differentiation | 1.77e-06 | 22 | 84 | 4 | GO:0030853 | |
| GeneOntologyBiologicalProcess | negative regulation of platelet aggregation | 2.14e-06 | 23 | 84 | 4 | GO:0090331 | |
| GeneOntologyBiologicalProcess | regulation of natural killer cell mediated cytotoxicity directed against tumor cell target | 2.14e-06 | 23 | 84 | 4 | GO:0002858 | |
| GeneOntologyBiologicalProcess | positive regulation of vasculogenesis | 2.56e-06 | 24 | 84 | 4 | GO:2001214 | |
| GeneOntologyBiologicalProcess | regulation of natural killer cell mediated immune response to tumor cell | 2.56e-06 | 24 | 84 | 4 | GO:0002855 | |
| GeneOntologyBiologicalProcess | natural killer cell mediated cytotoxicity directed against tumor cell target | 2.56e-06 | 24 | 84 | 4 | GO:0002420 | |
| GeneOntologyBiologicalProcess | common myeloid progenitor cell proliferation | 3.03e-06 | 25 | 84 | 4 | GO:0035726 | |
| GeneOntologyBiologicalProcess | natural killer cell mediated immune response to tumor cell | 3.03e-06 | 25 | 84 | 4 | GO:0002423 | |
| GeneOntologyBiologicalProcess | regulation of fat cell proliferation | 4.18e-06 | 27 | 84 | 4 | GO:0070344 | |
| GeneOntologyBiologicalProcess | granulocyte differentiation | 4.55e-06 | 60 | 84 | 5 | GO:0030851 | |
| GeneOntologyBiologicalProcess | negative regulation of homotypic cell-cell adhesion | 4.86e-06 | 28 | 84 | 4 | GO:0034111 | |
| GeneOntologyBiologicalProcess | regulation of vasculogenesis | 5.62e-06 | 29 | 84 | 4 | GO:2001212 | |
| GeneOntologyBiologicalProcess | negative regulation of platelet activation | 7.41e-06 | 31 | 84 | 4 | GO:0010544 | |
| GeneOntologyBiologicalProcess | regulation of endothelial cell differentiation | 7.87e-06 | 67 | 84 | 5 | GO:0045601 | |
| GeneOntologyBiologicalProcess | negative regulation of bone resorption | 8.44e-06 | 32 | 84 | 4 | GO:0045779 | |
| GeneOntologyBiologicalProcess | fat cell proliferation | 8.44e-06 | 32 | 84 | 4 | GO:0070341 | |
| GeneOntologyBiologicalProcess | regulation of blood vessel remodeling | 8.44e-06 | 32 | 84 | 4 | GO:0060312 | |
| GeneOntologyBiologicalProcess | regulation of granulocyte differentiation | 9.57e-06 | 33 | 84 | 4 | GO:0030852 | |
| GeneOntologyBiologicalProcess | negative regulation of feeding behavior | 9.57e-06 | 33 | 84 | 4 | GO:2000252 | |
| GeneOntologyBiologicalProcess | regulation of bone resorption | 9.76e-06 | 70 | 84 | 5 | GO:0045124 | |
| GeneOntologyBiologicalProcess | negative regulation of vascular permeability | 1.08e-05 | 34 | 84 | 4 | GO:0043116 | |
| GeneOntologyBiologicalProcess | negative regulation of bone remodeling | 1.08e-05 | 34 | 84 | 4 | GO:0046851 | |
| GeneOntologyBiologicalProcess | negative regulation of interleukin-1 production | 1.12e-05 | 72 | 84 | 5 | GO:0032692 | |
| GeneOntologyBiologicalProcess | insulin metabolic process | 1.22e-05 | 35 | 84 | 4 | GO:1901142 | |
| GeneOntologyBiologicalProcess | regulation of hepatocyte proliferation | 1.70e-05 | 38 | 84 | 4 | GO:2000345 | |
| GeneOntologyBiologicalProcess | regulation of bone remodeling | 1.88e-05 | 80 | 84 | 5 | GO:0046850 | |
| GeneOntologyBiologicalProcess | negative regulation of fatty acid biosynthetic process | 1.89e-05 | 39 | 84 | 4 | GO:0045717 | |
| GeneOntologyBiologicalProcess | negative regulation of natural killer cell mediated cytotoxicity | 2.09e-05 | 40 | 84 | 4 | GO:0045953 | |
| GeneOntologyBiologicalProcess | negative regulation of natural killer cell mediated immunity | 2.31e-05 | 41 | 84 | 4 | GO:0002716 | |
| GeneOntologyBiologicalProcess | regulation of sprouting angiogenesis | 2.52e-05 | 85 | 84 | 5 | GO:1903670 | |
| GeneOntologyBiologicalProcess | regulation of platelet aggregation | 2.55e-05 | 42 | 84 | 4 | GO:0090330 | |
| GeneOntologyBiologicalProcess | negative regulation of behavior | 3.36e-05 | 45 | 84 | 4 | GO:0048521 | |
| GeneOntologyBiologicalProcess | epithelial cell proliferation involved in liver morphogenesis | 3.67e-05 | 46 | 84 | 4 | GO:0072575 | |
| GeneOntologyBiologicalProcess | hepatocyte proliferation | 3.67e-05 | 46 | 84 | 4 | GO:0072574 | |
| GeneOntologyBiologicalProcess | artery morphogenesis | 3.70e-05 | 92 | 84 | 5 | GO:0048844 | |
| GeneOntologyBiologicalProcess | negative regulation of leukocyte mediated cytotoxicity | 3.99e-05 | 47 | 84 | 4 | GO:0001911 | |
| GeneOntologyBiologicalProcess | bile acid and bile salt transport | 3.99e-05 | 47 | 84 | 4 | GO:0015721 | |
| GeneOntologyBiologicalProcess | negative regulation of tissue remodeling | 3.99e-05 | 47 | 84 | 4 | GO:0034104 | |
| GeneOntologyBiologicalProcess | liver morphogenesis | 4.72e-05 | 49 | 84 | 4 | GO:0072576 | |
| GeneOntologyBiologicalProcess | regulation of immune response to tumor cell | 4.72e-05 | 49 | 84 | 4 | GO:0002837 | |
| GeneOntologyBiologicalProcess | regulation of response to tumor cell | 5.11e-05 | 50 | 84 | 4 | GO:0002834 | |
| GeneOntologyBiologicalProcess | bone resorption | 5.26e-05 | 99 | 84 | 5 | GO:0045453 | |
| GeneOntologyBiologicalProcess | negative regulation of cell killing | 5.97e-05 | 52 | 84 | 4 | GO:0031342 | |
| GeneOntologyBiologicalProcess | behavior | NPC1 ACE2 PSG1 PSG3 P2RX2 PSG9 SCN9A CHD8 PSG8 CHD7 PTGER4 CRBN ADGRL3 | 6.10e-05 | 891 | 84 | 13 | GO:0007610 |
| GeneOntologyBiologicalProcess | regulation of homotypic cell-cell adhesion | 6.44e-05 | 53 | 84 | 4 | GO:0034110 | |
| GeneOntologyBiologicalProcess | immune response to tumor cell | 8.00e-05 | 56 | 84 | 4 | GO:0002418 | |
| GeneOntologyBiologicalProcess | tissue remodeling | 9.70e-05 | 262 | 84 | 7 | GO:0048771 | |
| GeneOntologyBiologicalProcess | negative regulation of osteoclast differentiation | 9.82e-05 | 59 | 84 | 4 | GO:0045671 | |
| GeneOntologyBiologicalProcess | negative regulation of innate immune response | 1.03e-04 | 114 | 84 | 5 | GO:0045824 | |
| GeneOntologyBiologicalProcess | negative regulation of fatty acid metabolic process | 1.05e-04 | 60 | 84 | 4 | GO:0045922 | |
| GeneOntologyBiologicalProcess | regulation of feeding behavior | 1.12e-04 | 61 | 84 | 4 | GO:0060259 | |
| GeneOntologyBiologicalProcess | vasculogenesis | 1.21e-04 | 118 | 84 | 5 | GO:0001570 | |
| GeneOntologyBiologicalProcess | regulation of platelet activation | 1.52e-04 | 66 | 84 | 4 | GO:0010543 | |
| GeneOntologyBiologicalProcess | positive regulation of melanocyte differentiation | 1.63e-04 | 5 | 84 | 2 | GO:0045636 | |
| GeneOntologyBiologicalProcess | bone remodeling | 1.71e-04 | 127 | 84 | 5 | GO:0046849 | |
| GeneOntologyBiologicalProcess | liver development | 1.77e-04 | 202 | 84 | 6 | GO:0001889 | |
| GeneOntologyBiologicalProcess | regulation of behavior | 1.77e-04 | 128 | 84 | 5 | GO:0050795 | |
| GeneOntologyBiologicalProcess | regulation of tissue remodeling | 1.77e-04 | 128 | 84 | 5 | GO:0034103 | |
| GeneOntologyBiologicalProcess | negative regulation of blood coagulation | 1.81e-04 | 69 | 84 | 4 | GO:0030195 | |
| GeneOntologyBiologicalProcess | positive regulation of MAP kinase activity | 1.84e-04 | 129 | 84 | 5 | GO:0043406 | |
| GeneOntologyBiologicalProcess | hepaticobiliary system development | 1.91e-04 | 205 | 84 | 6 | GO:0061008 | |
| GeneOntologyBiologicalProcess | negative regulation of hemostasis | 1.91e-04 | 70 | 84 | 4 | GO:1900047 | |
| GeneOntologyBiologicalProcess | regulation of vascular permeability | 2.02e-04 | 71 | 84 | 4 | GO:0043114 | |
| GeneOntologyBiologicalProcess | response to tumor cell | 2.02e-04 | 71 | 84 | 4 | GO:0002347 | |
| GeneOntologyBiologicalProcess | artery development | 2.12e-04 | 133 | 84 | 5 | GO:0060840 | |
| GeneOntologyBiologicalProcess | negative regulation of coagulation | 2.13e-04 | 72 | 84 | 4 | GO:0050819 | |
| GeneOntologyBiologicalProcess | regulation of fatty acid metabolic process | 2.20e-04 | 134 | 84 | 5 | GO:0019217 | |
| GeneOntologyBiologicalProcess | regulation of fatty acid biosynthetic process | 2.25e-04 | 73 | 84 | 4 | GO:0042304 | |
| GeneOntologyBiologicalProcess | negative regulation of response to external stimulus | 2.26e-04 | 509 | 84 | 9 | GO:0032102 | |
| GeneOntologyBiologicalProcess | negative regulation of IRE1-mediated unfolded protein response | 2.43e-04 | 6 | 84 | 2 | GO:1903895 | |
| GeneOntologyBiologicalProcess | regulation of natural killer cell mediated cytotoxicity | 2.63e-04 | 76 | 84 | 4 | GO:0042269 | |
| GeneOntologyBiologicalProcess | sprouting angiogenesis | 2.80e-04 | 220 | 84 | 6 | GO:0002040 | |
| GeneOntologyBiologicalProcess | cell-cell adhesion via plasma-membrane adhesion molecules | 2.89e-04 | 313 | 84 | 7 | GO:0098742 | |
| GeneOntologyBiologicalProcess | carbohydrate metabolic process | 2.90e-04 | 646 | 84 | 10 | GO:0005975 | |
| GeneOntologyBiologicalProcess | blood circulation | 2.98e-04 | 648 | 84 | 10 | GO:0008015 | |
| GeneOntologyBiologicalProcess | regulation of natural killer cell mediated immunity | 3.20e-04 | 80 | 84 | 4 | GO:0002715 | |
| GeneOntologyBiologicalProcess | aorta development | 3.20e-04 | 80 | 84 | 4 | GO:0035904 | |
| GeneOntologyBiologicalProcess | negative regulation of macrophage chemotaxis | 3.40e-04 | 7 | 84 | 2 | GO:0010760 | |
| GeneOntologyBiologicalProcess | positive regulation of pigment cell differentiation | 3.40e-04 | 7 | 84 | 2 | GO:0050942 | |
| GeneOntologyBiologicalProcess | regulation of melanocyte differentiation | 3.40e-04 | 7 | 84 | 2 | GO:0045634 | |
| GeneOntologyBiologicalProcess | regulation of vasculature development | 3.65e-04 | 430 | 84 | 8 | GO:1901342 | |
| GeneOntologyBiologicalProcess | negative regulation of lymphocyte mediated immunity | 3.68e-04 | 83 | 84 | 4 | GO:0002707 | |
| GeneOntologyBiologicalProcess | negative regulation of response to biotic stimulus | 3.82e-04 | 151 | 84 | 5 | GO:0002832 | |
| GeneOntologyBiologicalProcess | negative regulation of myeloid leukocyte differentiation | 4.03e-04 | 85 | 84 | 4 | GO:0002762 | |
| GeneOntologyBiologicalProcess | regulation of epidermal growth factor receptor signaling pathway | 4.22e-04 | 86 | 84 | 4 | GO:0042058 | |
| GeneOntologyCellularComponent | cell surface | SLAMF8 IL1RAPL1 MRC1 ACE2 CD6 IQGAP2 PSG1 PSG3 ADAMTS9 P2RX2 PSG7 MRC2 PSG9 PSG8 CUBN ACVRL1 CEACAM20 IL5RA | 2.79e-07 | 1111 | 83 | 18 | GO:0009986 |
| GeneOntologyCellularComponent | transforming growth factor beta ligand-receptor complex | 4.05e-07 | 16 | 83 | 4 | GO:0070021 | |
| GeneOntologyCellularComponent | T cell receptor complex | 4.71e-05 | 163 | 83 | 6 | GO:0042101 | |
| GeneOntologyCellularComponent | receptor complex | 1.00e-04 | 581 | 83 | 10 | GO:0043235 | |
| GeneOntologyCellularComponent | lateral plasma membrane | 4.55e-04 | 90 | 83 | 4 | GO:0016328 | |
| GeneOntologyCellularComponent | plasma membrane signaling receptor complex | 4.85e-04 | 350 | 83 | 7 | GO:0098802 | |
| GeneOntologyCellularComponent | apical part of cell | 5.62e-04 | 592 | 83 | 9 | GO:0045177 | |
| GeneOntologyCellularComponent | ciliary membrane | 6.29e-04 | 98 | 83 | 4 | GO:0060170 | |
| GeneOntologyCellularComponent | apical plasma membrane | 7.00e-04 | 487 | 83 | 8 | GO:0016324 | |
| GeneOntologyCellularComponent | plasma membrane protein complex | 1.08e-03 | 785 | 83 | 10 | GO:0098797 | |
| GeneOntologyCellularComponent | Cul4A-RING E3 ubiquitin ligase complex | 1.37e-03 | 14 | 83 | 2 | GO:0031464 | |
| GeneOntologyCellularComponent | transferase complex | 1.45e-03 | 963 | 83 | 11 | GO:1990234 | |
| GeneOntologyCellularComponent | cell projection membrane | 1.63e-03 | 431 | 83 | 7 | GO:0031253 | |
| GeneOntologyCellularComponent | voltage-gated sodium channel complex | 2.04e-03 | 17 | 83 | 2 | GO:0001518 | |
| GeneOntologyCellularComponent | transferase complex, transferring phosphorus-containing groups | 2.17e-03 | 335 | 83 | 6 | GO:0061695 | |
| MousePheno | decreased susceptibility to Coronaviridae infection | 3.02e-07 | 28 | 73 | 5 | MP:0020950 | |
| MousePheno | decreased susceptibility to Coronaviridae infection induced morbidity/mortality | 1.55e-06 | 17 | 73 | 4 | MP:0031047 | |
| MousePheno | increased skeletal muscle triglyceride level | 3.83e-06 | 21 | 73 | 4 | MP:0031415 | |
| MousePheno | abnormal susceptibility to Coronaviridae infection | 5.39e-06 | 49 | 73 | 5 | MP:0020948 | |
| MousePheno | decreased fatty acid oxidation | 6.72e-06 | 24 | 73 | 4 | MP:0014172 | |
| MousePheno | abnormal glycogen homeostasis | 9.82e-06 | 144 | 73 | 7 | MP:0005438 | |
| MousePheno | increased abdominal fat pad weight | 1.10e-05 | 27 | 73 | 4 | MP:0009286 | |
| MousePheno | abnormal brain cholesterol level | 1.60e-05 | 10 | 73 | 3 | MP:0012779 | |
| MousePheno | abnormal skeletal muscle triglyceride level | 1.94e-05 | 31 | 73 | 4 | MP:0031413 | |
| MousePheno | decreased carbon dioxide production | 1.94e-05 | 31 | 73 | 4 | MP:0008964 | |
| MousePheno | abnormal carbon dioxide production | 2.54e-05 | 67 | 73 | 5 | MP:0008962 | |
| MousePheno | decreased skeletal muscle cell glucose uptake | 3.17e-05 | 35 | 73 | 4 | MP:0031618 | |
| MousePheno | abnormal muscle triglyceride level | 3.55e-05 | 36 | 73 | 4 | MP:0031412 | |
| MousePheno | small cerebellum | 3.59e-05 | 119 | 73 | 6 | MP:0000852 | |
| MousePheno | decreased muscle cell glucose uptake | 4.90e-05 | 39 | 73 | 4 | MP:0030022 | |
| MousePheno | decreased susceptibility to Riboviria infection | 6.75e-05 | 82 | 73 | 5 | MP:0020914 | |
| MousePheno | decreased triglyceride level | 7.90e-05 | 348 | 73 | 9 | MP:0005318 | |
| MousePheno | decreased susceptibility to Riboviria infection induced morbidity/mortality | 7.93e-05 | 44 | 73 | 4 | MP:0031023 | |
| MousePheno | increased brain cholesterol level | 8.04e-05 | 3 | 73 | 2 | MP:0010162 | |
| MousePheno | increased brain sterol level | 8.04e-05 | 3 | 73 | 2 | MP:0012228 | |
| MousePheno | decreased circulating triglyceride level | 9.01e-05 | 275 | 73 | 8 | MP:0002644 | |
| MousePheno | abnormal skeletal muscle cell glucose uptake | 1.03e-04 | 47 | 73 | 4 | MP:0031617 | |
| MousePheno | decreased cellular glucose uptake | 1.65e-04 | 53 | 73 | 4 | MP:0003926 | |
| MousePheno | abnormal fatty acid oxidation | 1.78e-04 | 54 | 73 | 4 | MP:0010953 | |
| MousePheno | abnormal intestine regeneration | 2.66e-04 | 5 | 73 | 2 | MP:0003380 | |
| MousePheno | impaired intestine regeneration | 2.66e-04 | 5 | 73 | 2 | MP:0031319 | |
| MousePheno | decreased susceptibility to viral infection induced morbidity/mortality | 2.68e-04 | 60 | 73 | 4 | MP:0009790 | |
| MousePheno | abnormal lipid oxidation | 2.85e-04 | 61 | 73 | 4 | MP:0010951 | |
| MousePheno | increased insulin secretion | 3.43e-04 | 64 | 73 | 4 | MP:0003058 | |
| MousePheno | abnormal luteinizing hormone level | 3.43e-04 | 64 | 73 | 4 | MP:0003969 | |
| MousePheno | decreased lipid level | NPC1 PDIA6 PSG1 PSG3 PSG9 INPPL1 DHCR7 APOL6 SERAC1 PSG8 CHD7 CRBN | 3.53e-04 | 727 | 73 | 12 | MP:0014461 |
| MousePheno | abnormal circulating hormone level | NPC1 MRC1 ACE2 PDIA6 PSG1 PSG3 PSG9 INPPL1 DHCR7 PSG8 CHD7 ACVRL1 NPFFR1 CRBN | 3.61e-04 | 954 | 73 | 14 | MP:0005418 |
| MousePheno | abnormal hormone level | NPC1 MRC1 ACE2 PDIA6 PSG1 PSG3 PSG9 INPPL1 DHCR7 PSG8 CHD7 ACVRL1 NPFFR1 CRBN ADGRL3 | 3.63e-04 | 1073 | 73 | 15 | MP:0003953 |
| MousePheno | decreased susceptibility to infection induced morbidity/mortality | 4.04e-04 | 120 | 73 | 5 | MP:0009786 | |
| MousePheno | abnormal muscle cell glucose uptake | 4.09e-04 | 67 | 73 | 4 | MP:0004130 | |
| MousePheno | abnormal abdominal fat pad morphology | 4.26e-04 | 262 | 73 | 7 | MP:0000010 | |
| MousePheno | abnormal lung weight | 4.33e-04 | 68 | 73 | 4 | MP:0005629 | |
| MousePheno | increased hormone level | NPC1 MRC1 ACE2 PSG1 PSG3 PSG9 DHCR7 PSG8 ACVRL1 NPFFR1 ADGRL3 | 4.61e-04 | 641 | 73 | 11 | MP:0014454 |
| MousePheno | decreased susceptibility to viral infection | 4.88e-04 | 125 | 73 | 5 | MP:0002410 | |
| MousePheno | increased susceptibility to otitis media | 5.53e-04 | 31 | 73 | 3 | MP:0001850 | |
| MousePheno | decreased brain cholesterol level | 5.55e-04 | 7 | 73 | 2 | MP:0010161 | |
| MousePheno | decreased brain sterol level | 5.55e-04 | 7 | 73 | 2 | MP:0012227 | |
| MousePheno | abnormal vascular wound healing | 5.67e-04 | 73 | 73 | 4 | MP:0004883 | |
| MousePheno | abnormal endocrine gland physiology | 5.91e-04 | 363 | 73 | 8 | MP:0013561 | |
| MousePheno | decreased retina photoreceptor cell number | 5.98e-04 | 74 | 73 | 4 | MP:0001327 | |
| MousePheno | abnormal susceptibility to infection induced morbidity/mortality | 6.19e-04 | 279 | 73 | 7 | MP:0009785 | |
| MousePheno | abnormal lung vasculature morphology | 7.29e-04 | 78 | 73 | 4 | MP:0004007 | |
| MousePheno | abnormal cerebellum posterior lobe morphology | 7.38e-04 | 8 | 73 | 2 | MP:0009962 | |
| MousePheno | abnormal cerebellum posterior vermis morphology | 7.38e-04 | 8 | 73 | 2 | MP:0000869 | |
| MousePheno | abnormal lung cholesterol level | 7.38e-04 | 8 | 73 | 2 | MP:0031630 | |
| MousePheno | decreased oxygen consumption | 7.65e-04 | 79 | 73 | 4 | MP:0005290 | |
| MousePheno | increased circulating luteinizing hormone level | 7.93e-04 | 35 | 73 | 3 | MP:0001751 | |
| MousePheno | increased circulating hormone level | 8.02e-04 | 578 | 73 | 10 | MP:0014456 | |
| MousePheno | polyphagia | 8.02e-04 | 80 | 73 | 4 | MP:0001433 | |
| MousePheno | decreased retina cone cell number | 8.62e-04 | 36 | 73 | 3 | MP:0008446 | |
| MousePheno | abnormal cerebellum morphology | 9.27e-04 | 389 | 73 | 8 | MP:0000849 | |
| MousePheno | abnormal hair follicle melanin granule morphology | 9.46e-04 | 9 | 73 | 2 | MP:0005072 | |
| MousePheno | abnormal cerebellar cortex morphology | 9.49e-04 | 300 | 73 | 7 | MP:0004097 | |
| MousePheno | increased luteinizing hormone level | 1.01e-03 | 38 | 73 | 3 | MP:0005133 | |
| MousePheno | increased lung weight | 1.09e-03 | 39 | 73 | 3 | MP:0005630 | |
| MousePheno | ear inflammation | 1.18e-03 | 40 | 73 | 3 | MP:0001849 | |
| MousePheno | abnormal colon morphology | 1.18e-03 | 152 | 73 | 5 | MP:0000495 | |
| MousePheno | abnormal energy expenditure | 1.21e-03 | 313 | 73 | 7 | MP:0005450 | |
| MousePheno | abnormal fat pad morphology | 1.24e-03 | 314 | 73 | 7 | MP:0005334 | |
| MousePheno | abnormal response to antigen | 1.29e-03 | 726 | 73 | 11 | MP:0020000 | |
| MousePheno | abnormal energy homeostasis | 1.43e-03 | 322 | 73 | 7 | MP:0005448 | |
| MousePheno | increased macrophage apoptosis | 1.44e-03 | 11 | 73 | 2 | MP:0011080 | |
| MousePheno | abnormal circulating leptin level | 1.44e-03 | 236 | 73 | 6 | MP:0005667 | |
| MousePheno | abnormal metencephalon morphology | 1.51e-03 | 420 | 73 | 8 | MP:0000847 | |
| Domain | BRK | 9.75e-12 | 6 | 84 | 5 | SM00592 | |
| Domain | BRK_domain | 9.75e-12 | 6 | 84 | 5 | IPR006576 | |
| Domain | BRK | 9.75e-12 | 6 | 84 | 5 | PF07533 | |
| Domain | SNF2_N | 5.70e-09 | 32 | 84 | 6 | IPR000330 | |
| Domain | SNF2_N | 5.70e-09 | 32 | 84 | 6 | PF00176 | |
| Domain | Chromo_domain | 6.48e-08 | 24 | 84 | 5 | IPR023780 | |
| Domain | Chromo | 9.96e-08 | 26 | 84 | 5 | PF00385 | |
| Domain | CHROMO_1 | 1.48e-07 | 28 | 84 | 5 | PS00598 | |
| Domain | CHROMO_2 | 1.48e-07 | 28 | 84 | 5 | PS50013 | |
| Domain | Chromodomain-like | 2.99e-07 | 32 | 84 | 5 | IPR016197 | |
| Domain | Chromo/shadow_dom | 3.51e-07 | 33 | 84 | 5 | IPR000953 | |
| Domain | CHROMO | 3.51e-07 | 33 | 84 | 5 | SM00298 | |
| Domain | ig | 2.23e-06 | 190 | 84 | 8 | PF00047 | |
| Domain | Immunoglobulin | 2.23e-06 | 190 | 84 | 8 | IPR013151 | |
| Domain | Helicase_C | 8.69e-06 | 107 | 84 | 6 | PF00271 | |
| Domain | HELICc | 8.69e-06 | 107 | 84 | 6 | SM00490 | |
| Domain | Helicase_C | 9.16e-06 | 108 | 84 | 6 | IPR001650 | |
| Domain | HELICASE_CTER | 9.66e-06 | 109 | 84 | 6 | PS51194 | |
| Domain | HELICASE_ATP_BIND_1 | 9.66e-06 | 109 | 84 | 6 | PS51192 | |
| Domain | DEXDc | 9.66e-06 | 109 | 84 | 6 | SM00487 | |
| Domain | Helicase_ATP-bd | 1.02e-05 | 110 | 84 | 6 | IPR014001 | |
| Domain | SAM_1 | 1.36e-05 | 68 | 84 | 5 | PF00536 | |
| Domain | DNA/RNA_helicase_DEAH_CS | 1.79e-05 | 35 | 84 | 4 | IPR002464 | |
| Domain | Ig_2 | 1.93e-05 | 73 | 84 | 5 | PF13895 | |
| Domain | Pept_M12B_GON-ADAMTSs | 2.00e-05 | 2 | 84 | 2 | IPR012314 | |
| Domain | GON | 2.00e-05 | 2 | 84 | 2 | PF08685 | |
| Domain | GON | 2.00e-05 | 2 | 84 | 2 | PS51046 | |
| Domain | - | 2.43e-05 | 13 | 84 | 3 | 2.10.10.10 | |
| Domain | DEAH_ATP_HELICASE | 2.50e-05 | 38 | 84 | 4 | PS00690 | |
| Domain | FN_type2_col-bd | 3.08e-05 | 14 | 84 | 3 | IPR000562 | |
| Domain | FN2_2 | 3.08e-05 | 14 | 84 | 3 | PS51092 | |
| Domain | fn2 | 3.08e-05 | 14 | 84 | 3 | PF00040 | |
| Domain | FN2_1 | 3.08e-05 | 14 | 84 | 3 | PS00023 | |
| Domain | FN2 | 3.08e-05 | 14 | 84 | 3 | SM00059 | |
| Domain | SAM | 4.77e-05 | 88 | 84 | 5 | SM00454 | |
| Domain | SAM_DOMAIN | 6.88e-05 | 95 | 84 | 5 | PS50105 | |
| Domain | SAM | 7.60e-05 | 97 | 84 | 5 | IPR001660 | |
| Domain | IGc2 | 9.08e-05 | 235 | 84 | 7 | SM00408 | |
| Domain | Ig_sub2 | 9.08e-05 | 235 | 84 | 7 | IPR003598 | |
| Domain | - | 1.16e-04 | 106 | 84 | 5 | 1.10.150.50 | |
| Domain | ADAM_spacer1 | 1.46e-04 | 23 | 84 | 3 | IPR010294 | |
| Domain | ADAM_spacer1 | 1.46e-04 | 23 | 84 | 3 | PF05986 | |
| Domain | SAM/pointed | 1.84e-04 | 117 | 84 | 5 | IPR013761 | |
| Domain | TSP_1 | 1.85e-04 | 63 | 84 | 4 | PF00090 | |
| Domain | TSP1 | 2.09e-04 | 65 | 84 | 4 | SM00209 | |
| Domain | TSP1_rpt | 2.09e-04 | 65 | 84 | 4 | IPR000884 | |
| Domain | TSP1 | 2.09e-04 | 65 | 84 | 4 | PS50092 | |
| Domain | Ig-like_fold | SLAMF8 SEMA3A IL1RAPL1 AREL1 PSG1 PSG3 PSG7 PSG9 PSG8 CEACAM20 IL5RA | 3.14e-04 | 706 | 84 | 11 | IPR013783 |
| Domain | IG_LIKE | 3.57e-04 | 491 | 84 | 9 | PS50835 | |
| Domain | Kringle-like | 3.96e-04 | 32 | 84 | 3 | IPR013806 | |
| Domain | ZF_CCHHC | 4.14e-04 | 7 | 84 | 2 | PS51802 | |
| Domain | Ig-like_dom | 4.26e-04 | 503 | 84 | 9 | IPR007110 | |
| Domain | IG | 6.09e-04 | 421 | 84 | 8 | SM00409 | |
| Domain | Ig_sub | 6.09e-04 | 421 | 84 | 8 | IPR003599 | |
| Domain | MBT | 7.05e-04 | 9 | 84 | 2 | SM00561 | |
| Domain | MBT | 7.05e-04 | 9 | 84 | 2 | PS51079 | |
| Domain | - | SEMA3A IL1RAPL1 AREL1 PSG1 PSG3 PSG7 PSG9 PSG8 CEACAM20 IL5RA | 7.69e-04 | 663 | 84 | 10 | 2.60.40.10 |
| Domain | MBT | 8.79e-04 | 10 | 84 | 2 | PF02820 | |
| Domain | Mbt | 8.79e-04 | 10 | 84 | 2 | IPR004092 | |
| Domain | V-set | 1.45e-03 | 184 | 84 | 5 | PF07686 | |
| Domain | Dynein_heavy_chain_D4_dom | 1.76e-03 | 14 | 84 | 2 | IPR024317 | |
| Domain | Dynein_HC_stalk | 1.76e-03 | 14 | 84 | 2 | IPR024743 | |
| Domain | MT | 1.76e-03 | 14 | 84 | 2 | PF12777 | |
| Domain | AAA_8 | 1.76e-03 | 14 | 84 | 2 | PF12780 | |
| Domain | DHC_fam | 2.02e-03 | 15 | 84 | 2 | IPR026983 | |
| Domain | Dynein_heavy_dom | 2.02e-03 | 15 | 84 | 2 | IPR004273 | |
| Domain | Dynein_heavy | 2.02e-03 | 15 | 84 | 2 | PF03028 | |
| Domain | Ig_V-set | 2.04e-03 | 199 | 84 | 5 | IPR013106 | |
| Domain | Metal_Hydrolase | 5.17e-03 | 24 | 84 | 2 | IPR032466 | |
| Pathway | REACTOME_O_LINKED_GLYCOSYLATION | 9.69e-06 | 109 | 64 | 6 | MM15164 | |
| Pathway | REACTOME_O_LINKED_GLYCOSYLATION | 1.08e-05 | 111 | 64 | 6 | M27416 | |
| Pathway | REACTOME_DISEASES_ASSOCIATED_WITH_O_GLYCOSYLATION_OF_PROTEINS | 1.38e-05 | 68 | 64 | 5 | M27303 | |
| Pathway | REACTOME_O_GLYCOSYLATION_OF_TSR_DOMAIN_CONTAINING_PROTEINS | 2.82e-05 | 39 | 64 | 4 | M27417 | |
| Pathway | REACTOME_O_GLYCOSYLATION_OF_TSR_DOMAIN_CONTAINING_PROTEINS | 2.82e-05 | 39 | 64 | 4 | MM15165 | |
| Pubmed | 1.52e-10 | 14 | 85 | 5 | 25908210 | ||
| Pubmed | Control of mouse hepatitis virus replication in macrophages by a recessive gene on chromosome 7. | 2.28e-10 | 15 | 85 | 5 | 6327825 | |
| Pubmed | In vivo validation of late-onset Alzheimer's disease genetic risk factors. | 3.96e-09 | 25 | 85 | 5 | 38687251 | |
| Pubmed | 4.19e-09 | 54 | 85 | 6 | 8482578 | ||
| Pubmed | 1.41e-08 | 3 | 85 | 3 | 2341148 | ||
| Pubmed | 1.41e-08 | 3 | 85 | 3 | 28533432 | ||
| Pubmed | A mouse carcinoembryonic antigen gene family member is a calcium-dependent cell adhesion molecule. | 2.34e-08 | 13 | 85 | 4 | 1985902 | |
| Pubmed | CEACAM1+ myeloid cells control angiogenesis in inflammation. | 2.34e-08 | 13 | 85 | 4 | 19273835 | |
| Pubmed | Mechanism of glucose intolerance in mice with dominant negative mutation of CEACAM1. | 2.34e-08 | 13 | 85 | 4 | 16638824 | |
| Pubmed | 2.34e-08 | 13 | 85 | 4 | 20044046 | ||
| Pubmed | 2.34e-08 | 13 | 85 | 4 | 32150576 | ||
| Pubmed | 2.34e-08 | 13 | 85 | 4 | 6265583 | ||
| Pubmed | 2.34e-08 | 13 | 85 | 4 | 34440862 | ||
| Pubmed | CEACAM1 is a potent regulator of B cell receptor complex-induced activation. | 2.34e-08 | 13 | 85 | 4 | 12832451 | |
| Pubmed | 2.34e-08 | 13 | 85 | 4 | 25406283 | ||
| Pubmed | Crystal structure of mouse coronavirus receptor-binding domain complexed with its murine receptor. | 2.34e-08 | 13 | 85 | 4 | 21670291 | |
| Pubmed | 2.34e-08 | 13 | 85 | 4 | 22162753 | ||
| Pubmed | 2.34e-08 | 13 | 85 | 4 | 2702644 | ||
| Pubmed | 2.34e-08 | 13 | 85 | 4 | 8380065 | ||
| Pubmed | 2.34e-08 | 13 | 85 | 4 | 1279194 | ||
| Pubmed | 2.34e-08 | 13 | 85 | 4 | 25724769 | ||
| Pubmed | 2.34e-08 | 13 | 85 | 4 | 26374765 | ||
| Pubmed | CEACAM1 deficiency delays important wound healing processes. | 2.34e-08 | 13 | 85 | 4 | 22092845 | |
| Pubmed | 2.34e-08 | 13 | 85 | 4 | 11801635 | ||
| Pubmed | 2.34e-08 | 13 | 85 | 4 | 28913658 | ||
| Pubmed | Expression of the Bgp gene and characterization of mouse colon biliary glycoprotein isoforms. | 2.34e-08 | 13 | 85 | 4 | 8500759 | |
| Pubmed | Mouse susceptibility to mouse hepatitis virus infection is linked to viral receptor genotype. | 2.34e-08 | 13 | 85 | 4 | 9343248 | |
| Pubmed | Ceacam1 deletion causes vascular alterations in large vessels. | 2.34e-08 | 13 | 85 | 4 | 23800882 | |
| Pubmed | 2.34e-08 | 13 | 85 | 4 | 19285068 | ||
| Pubmed | 2.34e-08 | 13 | 85 | 4 | 21760897 | ||
| Pubmed | 2.34e-08 | 13 | 85 | 4 | 1719235 | ||
| Pubmed | Mouse hepatitis virus utilizes two carcinoembryonic antigens as alternative receptors. | 2.34e-08 | 13 | 85 | 4 | 1326665 | |
| Pubmed | Conditional deletion of CEACAM1 in hepatic stellate cells causes their activation. | 2.34e-08 | 13 | 85 | 4 | 39168268 | |
| Pubmed | 2.34e-08 | 13 | 85 | 4 | 8402684 | ||
| Pubmed | 2.34e-08 | 13 | 85 | 4 | 16619040 | ||
| Pubmed | 2.34e-08 | 13 | 85 | 4 | 29377208 | ||
| Pubmed | Expression of MHV-A59 receptor glycoproteins in susceptible and resistant strains of mice. | 2.34e-08 | 13 | 85 | 4 | 8209741 | |
| Pubmed | 2.34e-08 | 13 | 85 | 4 | 27002145 | ||
| Pubmed | Mice with null mutation of Ceacam I develop nonalcoholic steatohepatitis. | 2.34e-08 | 13 | 85 | 4 | 21949477 | |
| Pubmed | 2.34e-08 | 13 | 85 | 4 | 26219866 | ||
| Pubmed | 2.34e-08 | 13 | 85 | 4 | 2133556 | ||
| Pubmed | 2.34e-08 | 13 | 85 | 4 | 32521208 | ||
| Pubmed | 2.34e-08 | 13 | 85 | 4 | 19406938 | ||
| Pubmed | 2.34e-08 | 13 | 85 | 4 | 19621080 | ||
| Pubmed | CEACAM1 promotes CD8+ T cell responses and improves control of a chronic viral infection. | 2.34e-08 | 13 | 85 | 4 | 29967450 | |
| Pubmed | Expression of newly identified secretory CEACAM1(a) isoforms in the intestinal epithelium. | 2.34e-08 | 13 | 85 | 4 | 19358828 | |
| Pubmed | 2.34e-08 | 13 | 85 | 4 | 16680193 | ||
| Pubmed | 2.34e-08 | 13 | 85 | 4 | 1653760 | ||
| Pubmed | Regulation of hepatic fibrosis by carcinoembryonic antigen-related cell adhesion molecule 1. | 2.34e-08 | 13 | 85 | 4 | 34058224 | |
| Pubmed | 2.34e-08 | 13 | 85 | 4 | 10964771 | ||
| Pubmed | 2.34e-08 | 13 | 85 | 4 | 32169849 | ||
| Pubmed | 2.34e-08 | 13 | 85 | 4 | 22469976 | ||
| Pubmed | CEACAM1 creates a pro-angiogenic tumor microenvironment that supports tumor vessel maturation. | 2.34e-08 | 13 | 85 | 4 | 21532628 | |
| Pubmed | Structural and Molecular Evidence Suggesting Coronavirus-driven Evolution of Mouse Receptor. | 2.34e-08 | 13 | 85 | 4 | 28035001 | |
| Pubmed | Interaction between altered insulin and lipid metabolism in CEACAM1-inactive transgenic mice. | 2.34e-08 | 13 | 85 | 4 | 15316023 | |
| Pubmed | In vivo adaptation and persistence of Neisseria meningitidis within the nasopharyngeal mucosa. | 2.34e-08 | 13 | 85 | 4 | 23935487 | |
| Pubmed | 2.34e-08 | 13 | 85 | 4 | 15331748 | ||
| Pubmed | 2.34e-08 | 13 | 85 | 4 | 22673933 | ||
| Pubmed | Tumor angiogenesis mediated by myeloid cells is negatively regulated by CEACAM1. | 2.34e-08 | 13 | 85 | 4 | 22406619 | |
| Pubmed | 2.34e-08 | 13 | 85 | 4 | 7628460 | ||
| Pubmed | Forced Hepatic Overexpression of CEACAM1 Curtails Diet-Induced Insulin Resistance. | 2.34e-08 | 13 | 85 | 4 | 25972571 | |
| Pubmed | 2.34e-08 | 13 | 85 | 4 | 19008452 | ||
| Pubmed | 2.34e-08 | 13 | 85 | 4 | 18544705 | ||
| Pubmed | Expression of the mouse hepatitis virus receptor by central nervous system microglia. | 2.34e-08 | 13 | 85 | 4 | 15220458 | |
| Pubmed | 2.34e-08 | 13 | 85 | 4 | 18843289 | ||
| Pubmed | 2.34e-08 | 13 | 85 | 4 | 15207636 | ||
| Pubmed | 2.34e-08 | 13 | 85 | 4 | 21081647 | ||
| Pubmed | 2.34e-08 | 13 | 85 | 4 | 11133662 | ||
| Pubmed | 2.34e-08 | 13 | 85 | 4 | 11483763 | ||
| Pubmed | 2.34e-08 | 13 | 85 | 4 | 2164599 | ||
| Pubmed | 2.34e-08 | 13 | 85 | 4 | 29396368 | ||
| Pubmed | 2.34e-08 | 13 | 85 | 4 | 18003729 | ||
| Pubmed | 2.34e-08 | 13 | 85 | 4 | 26284027 | ||
| Pubmed | CEACAM1 specifically suppresses B cell receptor signaling-mediated activation. | 2.34e-08 | 13 | 85 | 4 | 33352461 | |
| Pubmed | 2.34e-08 | 13 | 85 | 4 | 38381498 | ||
| Pubmed | 2.34e-08 | 13 | 85 | 4 | 20739537 | ||
| Pubmed | 2.34e-08 | 13 | 85 | 4 | 1633107 | ||
| Pubmed | The role of CEA-related cell adhesion molecule-1 (CEACAM1) in vascular homeostasis. | 2.34e-08 | 13 | 85 | 4 | 27695943 | |
| Pubmed | 2.34e-08 | 13 | 85 | 4 | 20404914 | ||
| Pubmed | 2.34e-08 | 13 | 85 | 4 | 26911181 | ||
| Pubmed | Hepatic CEACAM1 expression indicates donor liver quality and prevents early transplantation injury. | 2.34e-08 | 13 | 85 | 4 | 32027621 | |
| Pubmed | 2.34e-08 | 13 | 85 | 4 | 30664851 | ||
| Pubmed | Role for hepatic CEACAM1 in regulating fatty acid metabolism along the adipocyte-hepatocyte axis. | 2.34e-08 | 13 | 85 | 4 | 27777319 | |
| Pubmed | 2.34e-08 | 13 | 85 | 4 | 18848945 | ||
| Pubmed | 3.26e-08 | 14 | 85 | 4 | 37531413 | ||
| Pubmed | Human CEACAM1-LF regulates lipid storage in HepG2 cells via fatty acid transporter CD36. | 3.26e-08 | 14 | 85 | 4 | 34666041 | |
| Pubmed | 3.26e-08 | 14 | 85 | 4 | 34619794 | ||
| Pubmed | SHP1 phosphatase-dependent T cell inhibition by CEACAM1 adhesion molecule isoforms. | 3.26e-08 | 14 | 85 | 4 | 17081782 | |
| Pubmed | Loss of Ceacam1 promotes prostate cancer progression in Pten haploinsufficient male mice. | 3.26e-08 | 14 | 85 | 4 | 32209360 | |
| Pubmed | 3.26e-08 | 14 | 85 | 4 | 11994468 | ||
| Pubmed | 3.26e-08 | 14 | 85 | 4 | 11850617 | ||
| Pubmed | 3.26e-08 | 14 | 85 | 4 | 20381490 | ||
| Pubmed | CEACAM1 regulates integrin αIIbβ3-mediated functions in platelets. | 3.26e-08 | 14 | 85 | 4 | 26196244 | |
| Pubmed | 3.26e-08 | 14 | 85 | 4 | 8896983 | ||
| Pubmed | 3.26e-08 | 14 | 85 | 4 | 22962327 | ||
| Pubmed | 3.26e-08 | 14 | 85 | 4 | 17623671 | ||
| Pubmed | 3.26e-08 | 14 | 85 | 4 | 26846848 | ||
| Pubmed | CEACAM1, a SOX9 direct transcriptional target identified in the colon epithelium. | 3.26e-08 | 14 | 85 | 4 | 18794798 | |
| Pubmed | 3.26e-08 | 14 | 85 | 4 | 23469261 | ||
| Pubmed | 3.26e-08 | 14 | 85 | 4 | 18454175 | ||
| Interaction | PSG4 interactions | 3.85e-06 | 8 | 84 | 3 | int:PSG4 | |
| Cytoband | 19q13.2 | 1.43e-05 | 164 | 85 | 5 | 19q13.2 | |
| GeneFamily | CD molecules|V-set domain containing|Pregnancy specific glycoproteins | 1.19e-10 | 11 | 57 | 5 | 1315 | |
| GeneFamily | Sterile alpha motif domain containing | 8.35e-06 | 88 | 57 | 5 | 760 | |
| GeneFamily | Sterile alpha motif domain containing|MBT domain containing | 3.47e-04 | 9 | 57 | 2 | 1263 | |
| GeneFamily | Dyneins, axonemal | 1.29e-03 | 17 | 57 | 2 | 536 | |
| GeneFamily | ADAM metallopeptidase domain containing|CD molecules | 1.46e-03 | 394 | 57 | 6 | 471 | |
| GeneFamily | ADAM metallopeptidases with thrombospondin type 1 motif | 1.61e-03 | 19 | 57 | 2 | 50 | |
| GeneFamily | Adenosine receptors|V-set domain containing | 1.73e-03 | 163 | 57 | 4 | 590 | |
| GeneFamily | Immunoglobulin like domain containing | 3.20e-03 | 193 | 57 | 4 | 594 | |
| Coexpression | SWEET_LUNG_CANCER_KRAS_UP | MRC1 ACE2 PDIA6 PSG1 PSG3 REEP6 PDK3 PSG9 POLG PSG8 FUCA1 C5 | 1.54e-07 | 534 | 85 | 12 | MM1050 |
| Coexpression | GIBBONS_GENETIC_MOUSE_MODEL_LUNG_ADENOCARCINOMA_DOWN_IN_METASTASIS | 3.46e-06 | 32 | 85 | 4 | MM2 | |
| Coexpression | KRAS.600.LUNG.BREAST_UP.V1_DN | 4.03e-06 | 284 | 85 | 8 | M2885 | |
| Coexpression | OUYANG_PROSTATE_CANCER_MARKERS | 4.99e-06 | 35 | 85 | 4 | MM757 | |
| Coexpression | KRAS.LUNG.BREAST_UP.V1_DN | 6.72e-06 | 141 | 85 | 6 | M2898 | |
| Coexpression | DESCARTES_FETAL_PLACENTA_TROPHOBLAST_GIANT_CELLS | 1.32e-05 | 93 | 85 | 5 | M40279 | |
| Coexpression | WANG_RESPONSE_TO_BEXAROTENE_UP | 1.80e-05 | 48 | 85 | 4 | MM531 | |
| Coexpression | GSE27241_WT_CTRL_VS_DIGOXIN_TREATED_RORGT_KO_CD4_TCELL_IN_TH17_POLARIZING_CONDITIONS_UP | 2.08e-05 | 172 | 85 | 6 | M8234 | |
| Coexpression | GSE15659_NAIVE_CD4_TCELL_VS_ACTIVATED_TREG_UP | 3.98e-05 | 193 | 85 | 6 | M3549 | |
| Coexpression | GSE26495_NAIVE_VS_PD1LOW_CD8_TCELL_DN | 4.85e-05 | 200 | 85 | 6 | M4659 | |
| Coexpression | LIM_MAMMARY_STEM_CELL_DN | 8.64e-05 | 436 | 85 | 8 | MM1326 | |
| Coexpression | KRAS.BREAST_UP.V1_DN | 1.04e-04 | 143 | 85 | 5 | M2887 | |
| Coexpression | BYSTROEM_CORRELATED_WITH_IL5_DN | 1.05e-04 | 75 | 85 | 4 | MM605 | |
| ToppCell | 5'-Parenchyma_lung-Epithelial-Epithelial_transtional-secretory-nasal_mucosa_goblet_cell-Goblet_(nasal)-Goblet_(nasal)_L.0.2.0.1|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 6.62e-07 | 161 | 85 | 6 | 7c9d4410d7142a5f3a05418c994f69978c9ffa17 | |
| ToppCell | Brain_organoid-organoid_Kanton_Nature|Brain_organoid / Sample Type, Dataset, Time_group, and Cell type. | 1.49e-06 | 185 | 85 | 6 | 857c7ca8493e91ef1d0078ddafd6082020f9b169 | |
| ToppCell | LPS_IL1RA-Endothelial-Endothelial-Gen_Cap|LPS_IL1RA / Treatment groups by lineage, cell group, cell type | 2.34e-06 | 200 | 85 | 6 | dccec522ab0d7fff62ad6273b02aa9022dbbb8eb | |
| ToppCell | LV-16._Neuronal|World / Chamber and Cluster_Paper | 1.62e-05 | 165 | 85 | 5 | 6ed52cb756d21addf46c7f6c457458b01339fe04 | |
| ToppCell | P15-Epithelial-airway_epithelial_cell-ciliated_cell_of_airway|P15 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase | 1.71e-05 | 167 | 85 | 5 | 5c3d0763f73628c71c71f9883556bb4f1639f3cc | |
| ToppCell | LA-16._Neuronal|LA / Chamber and Cluster_Paper | 1.76e-05 | 168 | 85 | 5 | c55bbfbde8bb954f1cb9af82007bdd1f8070fee3 | |
| ToppCell | Striatum-Neuronal-Excitatory-eN3(Slc17a7_Gad1Gad2)-Excitatory_Neuron.Gad1Gad2.Sgol2a_(Very_small_cluster)|Striatum / BrainAtlas - Mouse McCarroll V32 | 1.81e-05 | 169 | 85 | 5 | c3bf0cb67f200d02d5a021754e9b2a68d23ea168 | |
| ToppCell | COVID-19_Severe-CD4+_CTL|World / disease group, cell group and cell class | 1.81e-05 | 169 | 85 | 5 | 8c8168ac93a808d7b4756e4491db2b2979df1c1f | |
| ToppCell | Striatum-Neuronal-Excitatory-eN3(Slc17a7_Gad1Gad2)-Excitatory_Neuron.Gad1Gad2.Sgol2a_(Very_small_cluster)--|Striatum / BrainAtlas - Mouse McCarroll V32 | 1.81e-05 | 169 | 85 | 5 | 5375eb52ebadccb7bfff997a11985f23e81014d6 | |
| ToppCell | Striatum-Neuronal-Excitatory-eN3(Slc17a7_Gad1Gad2)-Excitatory_Neuron.Gad1Gad2.Sgol2a_(Very_small_cluster)-|Striatum / BrainAtlas - Mouse McCarroll V32 | 1.81e-05 | 169 | 85 | 5 | 1c132d21255f5a5174ac38db4e91927f9093418e | |
| ToppCell | facs-Brain_Non-Myeloid-Cerebellum-24m-Mesenchymal-brain_pericyte|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.03e-05 | 173 | 85 | 5 | 2415b6ff49f334da570577d4e93484d024a3dbd5 | |
| ToppCell | facs-Brain_Non-Myeloid-Cerebellum-24m-Mesenchymal-Pericyte|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.03e-05 | 173 | 85 | 5 | 2acd0693a2dfe04e3c1b2125ea63efe92d13150b | |
| ToppCell | renal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell-Proximal_Tubule_Epithelial_Cell_Segment_3|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 2.20e-05 | 176 | 85 | 5 | 1595dbeee336a81e581325d63208ec6262664ee9 | |
| ToppCell | COVID-19_Severe-CD4+_CTL|COVID-19_Severe / disease group, cell group and cell class | 2.26e-05 | 177 | 85 | 5 | 34e9455790bae905dd91923792f4109d18b7686e | |
| ToppCell | 10x_3'_v2v3-Non-neoplastic-Myeloid-TAM-BDM-TAM-BDM_INF-A|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 2.39e-05 | 179 | 85 | 5 | 06d412fc096d88de168969466ce422f0ab5553b2 | |
| ToppCell | renal_medulla_nuclei-CKD+DKD_normotensive-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell-Proximal_Tubule_Epithelial_Cell_Segment_3|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group | 2.39e-05 | 179 | 85 | 5 | d1ef7e1cb00336118e387b47f4f8120f53584391 | |
| ToppCell | facs-Thymus-Thymus_Epithelium-18m-Lymphocytic-thymocyte|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.73e-05 | 184 | 85 | 5 | 2cbed6462fea2622871bb7e49b0df3d984239281 | |
| ToppCell | facs-Thymus-Thymus_Epithelium-18m-Lymphocytic|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.73e-05 | 184 | 85 | 5 | ea7a7e2bac46d4d2c31a5d576b38a032b5335062 | |
| ToppCell | facs-Thymus-Thymus_Epithelium-18m-Lymphocytic-proliferating_thymocyte;_DN_to_DP_transition,_dividing_(some_are_Cd8+/_Cd4+,_some_undergoing_VDJ_recombination)|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.73e-05 | 184 | 85 | 5 | 2b19a8c5f823e00812908b23e66bb4e563278aff | |
| ToppCell | Adult-Endothelial-alveolar_capillary_endothelial_cell_(Cap2;_aerocyte)|Adult / Lineage, Cell type, age group and donor | 3.02e-05 | 188 | 85 | 5 | e5cad03f4a64147fe8174e7f614cf45233ffb9b7 | |
| ToppCell | LPS_only-Endothelial-Endothelial-Alv_Gen_Intermediate|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 3.10e-05 | 189 | 85 | 5 | e82211b9dc7540e7a183be2cbcfae39fdf503949 | |
| ToppCell | Children_(3_yrs)-Immune-interstitial_macrophage_(C1Q_positive)-D032|Children_(3_yrs) / Lineage, Cell type, age group and donor | 3.18e-05 | 190 | 85 | 5 | 2d54fca50593fbd11fe13fc2bfaf937a05db776d | |
| ToppCell | LPS-IL1RA+antiTNF-Endothelial-Endothelial-Alv_Gen_Intermediate|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 3.18e-05 | 190 | 85 | 5 | a3c6eec6df052105ab78b7e3c78f94218d5912eb | |
| ToppCell | LPS-IL1RA-Endothelial-Endothelial-Alv_Gen_Intermediate|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 3.18e-05 | 190 | 85 | 5 | 106ea0bb7b99c697ffc5443d72343df2484250c7 | |
| ToppCell | LPS_only-Endothelial-Endothelial-Activated_Gen_Cap|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 3.60e-05 | 195 | 85 | 5 | 56efeb58df19f357d7d5ce87348d4f196a595421 | |
| ToppCell | CV-Moderate-6|Moderate / Virus stimulation, Condition and Cluster | 3.60e-05 | 195 | 85 | 5 | 2b8a72d7e755b9655c7a496000d10ff06e50862b | |
| ToppCell | CV-Moderate-6|CV / Virus stimulation, Condition and Cluster | 3.69e-05 | 196 | 85 | 5 | 7bced0cc2112697593c478fa291b8ed3941fb811 | |
| ToppCell | 10x5'v1-week_17-19-Mesenchymal_osteo-stroma-osteoblast_precursor|week_17-19 / cell types per 3 fetal stages;per 3',per 5' | 3.69e-05 | 196 | 85 | 5 | 57df2a57b35be9851ac0b1e5731baa53052511f0 | |
| ToppCell | 3'-GW_trimst-2-SmallIntestine-Mesenchymal-fibroblastic-Stromal_2_(NPY+)|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 3.78e-05 | 197 | 85 | 5 | d9e196c8b4a6ede4733946dbdba3331534954beb | |
| ToppCell | T_cells-CTLs|World / Immune cells in Kidney/Urine in Lupus Nephritis | 3.78e-05 | 197 | 85 | 5 | 2de34e20915a247bee75aa40495e23c20bb23e18 | |
| ToppCell | Control-Control-Lymphocyte-T/NK-CD4+_T_activated|Control / Disease, condition lineage and cell class | 3.87e-05 | 198 | 85 | 5 | ee71543559836fd59adc0da877b2ca538cba60cb | |
| ToppCell | Tracheal-10x3prime_v2-Stromal-Schwann-Schwann_nonmyelinating|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations | 3.96e-05 | 199 | 85 | 5 | a92718a3f1153b8d2196fd343ed5bc0ebc98cad7 | |
| ToppCell | 3'-GW_trimst-1.5-SmallIntestine-Mesenchymal-fibroblastic-Stromal_2_(NPY+)|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 3.96e-05 | 199 | 85 | 5 | 05777e92344aedabfb5a72207c6632dc64205534 | |
| ToppCell | Tracheal-10x3prime_v2-Stromal-Schwann|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations | 3.96e-05 | 199 | 85 | 5 | 8dc65662c3ca1db2ba0091332f0658abc0afc5de | |
| ToppCell | Parenchymal-NucSeq-Immune_Myeloid-Macrophage_other-Macrophage_intravascular|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 4.06e-05 | 200 | 85 | 5 | 179afc4bee7a2fd85a3b5dadf32544a63807c164 | |
| ToppCell | Striatum-Endothelial-MURAL-M1(Rgs5Acta2)-M1_2|Striatum / BrainAtlas - Mouse McCarroll V32 | 6.31e-05 | 112 | 85 | 4 | 88fcd0dc12b5c00804381fb7dd59a6a2a9f37419 | |
| ToppCell | Striatum-Endothelial-MURAL-M1(Rgs5Acta2)-M1_2-MURAL_Mural.Rgs5Acta2.Kcnj8_(Mural.Rgs5Acta2.Kcnj8)-|Striatum / BrainAtlas - Mouse McCarroll V32 | 6.31e-05 | 112 | 85 | 4 | fd4cc5190626cb262aae0a7f04559b0e9757270e | |
| ToppCell | Striatum-Endothelial-MURAL-M1(Rgs5Acta2)-M1_2-MURAL_Mural.Rgs5Acta2.Kcnj8_(Mural.Rgs5Acta2.Kcnj8)|Striatum / BrainAtlas - Mouse McCarroll V32 | 6.31e-05 | 112 | 85 | 4 | d652e6fae433a6b56bf2a448fba2cf6c5e558905 | |
| ToppCell | Hippocampus-Neuronal-Excitatory-eN1(Slc17a7)-eN1_2-Pvrl3|Hippocampus / BrainAtlas - Mouse McCarroll V32 | 1.03e-04 | 127 | 85 | 4 | 9bc55cb9f4bddb274930784d12a83b9dceb35cb7 | |
| ToppCell | TCGA-Cervix-Primary_Tumor-Cervical_Carcinoma-Keratinizing_Cervical_Squamous_Cell_Carcinoma-6|TCGA-Cervix / Sample_Type by Project: Shred V9 | 1.34e-04 | 136 | 85 | 4 | 2c723777fadc5946df67d3e992471d8134b827f4 | |
| ToppCell | COVID-19-kidney-Technical/muscle_(PCT)|kidney / Disease (COVID-19 only), tissue and cell type | 1.76e-04 | 146 | 85 | 4 | c55f1bdb6ac43b4118cb27ea7c879527e1afcbab | |
| ToppCell | RV-16._Neuronal|World / Chamber and Cluster_Paper | 1.90e-04 | 149 | 85 | 4 | 3a2f8c4173dcf9e3f8d3b8ffddbc597098adf7a9 | |
| ToppCell | LPS_only-Hematopoietic_Mast-Mast_cells|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.95e-04 | 150 | 85 | 4 | 7290e9a812b1b2f919e67ccde0acf52687ab138f | |
| ToppCell | LPS_only-Hematopoietic_Mast|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.95e-04 | 150 | 85 | 4 | 2c5078a1f769ba8153dee756b53d28eb7b434a96 | |
| ToppCell | 18-Airway-Epithelial-Goblet-like_secretory|Airway / Age, Tissue, Lineage and Cell class | 2.10e-04 | 153 | 85 | 4 | 14a60220e169ce642771636de982a7b02e5b2608 | |
| ToppCell | COVID-19-kidney-Technical/muscle_(Mes)|kidney / Disease (COVID-19 only), tissue and cell type | 2.43e-04 | 159 | 85 | 4 | 5335cbcdeaf2bbd0268bbfe0e45c8c0d288e640d | |
| ToppCell | PND07-Epithelial-Epithelial_Airway-Neurosecretory-Secretory|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 2.49e-04 | 160 | 85 | 4 | 028b5261a1da832d52f66fb620db83e5fbbd874a | |
| ToppCell | PND07-Epithelial-Epithelial_Airway-Neurosecretory-Secretory-Secretory_mature|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 2.49e-04 | 160 | 85 | 4 | 1f4ee446436726c3d373f56d87dd80b6a12e8b9e | |
| ToppCell | Primary_Visual_cortex_(V1C)-Neuronal-Inh_GABAergic-i_Gaba_2-GABA_VIP_2-Inh_L2-5_VIP_TOX2|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.68e-04 | 163 | 85 | 4 | 39181c58387189a815e7b3eb29fbd1dd4ee24d0a | |
| ToppCell | facs-BAT-Fat-18m-Lymphocytic-NK_cell|BAT / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.74e-04 | 164 | 85 | 4 | ab9c17f86b98e1a4d5db1bd3086edab1320ebda8 | |
| ToppCell | facs-Trachea-3m-Hematologic-myeloid-tracheal_macrophage-macrophage_of_tracheal_l15|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 2.74e-04 | 164 | 85 | 4 | 5ca7b69684a8bb12dd0b45e7ad94e30d16ed01ce | |
| ToppCell | facs-MAT-Fat-3m-Myeloid-macrophage|MAT / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.74e-04 | 164 | 85 | 4 | b81498c3934e0d52bf0329dc745e02966f9d8613 | |
| ToppCell | facs-Lung-EPCAM-3m-Myeloid-Myeloid_Dendritic_Type_1|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.80e-04 | 165 | 85 | 4 | 2477b0f1a0ea26184cf3cc4a9ffcdfa825cbc615 | |
| ToppCell | PND10-Immune-Immune_Lymphocytic_T/NK-Lymphocytic_T-CD8_T-CD8_T_prolif|PND10 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 2.80e-04 | 165 | 85 | 4 | 5f606959a060b1ae241217889560c6761ac73bbb | |
| ToppCell | Adult-Immune-interstitial_macrophage_(C1Q_positive)-D122|Adult / Lineage, Cell type, age group and donor | 2.87e-04 | 166 | 85 | 4 | be284e2e596390f05305c7bcfc316f87b963fc0b | |
| ToppCell | PBMC-Mild-Myeloid-cDC-cDC-cDC_11|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 2.87e-04 | 166 | 85 | 4 | b1bebcbe17386cb102b11d551e62d46156ce0c68 | |
| ToppCell | PBMC-Mild-Myeloid-cDC-cDC-cDC_11|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09) | 2.93e-04 | 167 | 85 | 4 | e44743b20a7435c579d8e999ddc4ca119d6753f2 | |
| ToppCell | facs-Lung-3m-Hematologic-myeloid-myeloid_dendritic_cell-myeloid_dendritic_type_1|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 2.93e-04 | 167 | 85 | 4 | fd84a99ea142d1684cdcf4a88ef1d541760bc78a | |
| ToppCell | LA-16._Neuronal|World / Chamber and Cluster_Paper | 3.00e-04 | 168 | 85 | 4 | 2fd1fd2a16ac1c5eb028f93cc3a2477c7747693e | |
| ToppCell | LPS-IL1RA+antiTNF-Epithelial_airway-Club_cells|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 3.07e-04 | 169 | 85 | 4 | 8c96e1baa38ec5e777e627ab9dbce025e771f2c0 | |
| ToppCell | Primary_Motor_Cortex_(M1)-Neuronal-Inh_GABAergic-i_Gaba_2-GABA_VIP_1-Inh_L1-5_VIP_KCNJ2|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 3.07e-04 | 169 | 85 | 4 | d161dd8eb22633392b6c6466ee9eff4042464149 | |
| ToppCell | LPS-IL1RA+antiTNF-Epithelial_airway-Club_cells-Airway|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 3.07e-04 | 169 | 85 | 4 | 86041be5d3aeab5b9269f7912791b944f325a1b4 | |
| ToppCell | LV-16._Neuronal|LV / Chamber and Cluster_Paper | 3.07e-04 | 169 | 85 | 4 | a8fc8ab0f0757e939e213efb61c03cfe390bf7d2 | |
| ToppCell | renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Fibroblast-kidney_interstitial_fibroblast-proliferative_fibroblast|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 3.07e-04 | 169 | 85 | 4 | a84490724a206c9bbb145f7ce08613f91d100ac4 | |
| ToppCell | COVID-19-Heart-CM_+_Macrophage|Heart / Disease (COVID-19 only), tissue and cell type | 3.14e-04 | 170 | 85 | 4 | 4232fe937909f93d3736988c707b8f95ce993398 | |
| ToppCell | droplet-Lung-21m-Hematologic-lymphocytic-CD8-positive,_alpha-beta_T_cell-CD8-positive,_alpha-beta_T_cell_l48|21m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 3.14e-04 | 170 | 85 | 4 | 070d8683d1a5cc7d594ff0453c961a9bf982c2d0 | |
| ToppCell | tumor_Lung-Endothelial_cells-EPCs|Endothelial_cells / Location, Cell class and cell subclass | 3.21e-04 | 171 | 85 | 4 | dcb6c41980008d0b9eeb54999faff77311554976 | |
| ToppCell | droplet-Trachea-3m-Hematologic-myeloid-granulocyte-|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 3.21e-04 | 171 | 85 | 4 | 41932c9e70829ee3d55ca5fdb74d290fc8229416 | |
| ToppCell | LPS-IL1RA-Lymphocytic_NKT-T_cells|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 3.28e-04 | 172 | 85 | 4 | 0fc692be845d4225ff8b63bf9195724fc8510c2c | |
| ToppCell | facs-Lung-ENDOMUCIN-18m-Lymphocytic-regulatory_T_cell|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.28e-04 | 172 | 85 | 4 | 10a1d1838492b8ce6dea08844353b51571432c56 | |
| ToppCell | facs-Lung-ENDOMUCIN-18m-Lymphocytic-Regulatory_T|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.28e-04 | 172 | 85 | 4 | d824e46c8040b0bb9235f9b8a2b35386b303caa0 | |
| ToppCell | droplet-Marrow-nan-24m-Myeloid-basophil|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.35e-04 | 173 | 85 | 4 | 6d2ceba4f89a228600e2b40aba81bb0eb81578c0 | |
| ToppCell | 5'-Parenchyma_lung-Immune_Myeloid-Myeloid_macrophage-alveolar_macrophage-Alveolar_macrophages-Alveolar_macrophages_L.1.0.5.0|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 3.43e-04 | 174 | 85 | 4 | d5c22b43531414951666ee7542a66ed9380e2d14 | |
| ToppCell | Anterior_Cingulate_gyrus_(CgG)-Neuronal-Inh_GABAergic-i_Gaba_2-GABA_VIP_2-Inh_L3-6_VIP_KCTD13|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 3.43e-04 | 174 | 85 | 4 | 62f5dc7086e1491fc90f005ccadfa1b772b52fad | |
| ToppCell | Mid-temporal_gyrus_(MTG)-Neuronal-Inh_GABAergic-i_Gaba_2-GABA_VIP_2-Inh_L2-6_VIP_VIP|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 3.50e-04 | 175 | 85 | 4 | e78bf0c33a741bb97e987e41ac33da9e623a08ec | |
| ToppCell | E16.5-Epithelial-Epithelial_Airway-Neurosecretory|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 3.50e-04 | 175 | 85 | 4 | 38dec78efc99fe23479cba68cfa441e62bd6a08b | |
| ToppCell | TCGA-Bone_and_Soft_Tissue-Primary_Tumor-Sarcoma-Dedifferentiated_Liposarcoma-4|TCGA-Bone_and_Soft_Tissue / Sample_Type by Project: Shred V9 | 3.50e-04 | 175 | 85 | 4 | 16849ea8f0985108baa2085f34c3de14a4f9f28b | |
| ToppCell | LPS-IL1RA+antiTNF-Lymphocytic_NKT-T_cells-T-cells|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 3.58e-04 | 176 | 85 | 4 | 9d4a4dfeebb5a8a0f3ab18c37c8ddc2cd2158575 | |
| ToppCell | saliva-Severe-critical_progression_d12-22_with-steroid-Myeloid-Dendritic|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k) | 3.58e-04 | 176 | 85 | 4 | e08e7a6dd0208acfbb8646d71915af822a64b5de | |
| ToppCell | LPS-IL1RA+antiTNF-Lymphocytic_NKT-T_cells|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 3.58e-04 | 176 | 85 | 4 | bb41e9478373726eb460af764de0277b2d09928e | |
| ToppCell | saliva-Severe-critical_progression_d12-22_with-steroid-Myeloid-Dendritic-conventional_dendritic_cell|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k) | 3.58e-04 | 176 | 85 | 4 | b8264cdda75c5145d8bf8ae00b3e05393fe9a92b | |
| ToppCell | Hippocampus|World / BrainAtlas - Mouse McCarroll V32 | 3.58e-04 | 176 | 85 | 4 | f120a703f6d2f2d5f55eae1aea2e6382a485828f | |
| ToppCell | Primary_Motor_Cortex_(M1)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_SST-Inh_L5-6_SST_ISOC1|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 3.58e-04 | 176 | 85 | 4 | d09e28606e2a6ed1f660898316765ca215085c18 | |
| ToppCell | CF-Lymphoid-pDC|CF / Disease state, Lineage and Cell class | 3.58e-04 | 176 | 85 | 4 | dd1e529a9e413bcaab43584afbe059e1464ffb53 | |
| ToppCell | LPS-antiTNF-Lymphocytic_NKT-T_cells|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 3.58e-04 | 176 | 85 | 4 | ea27e18407b8a13e8212830da859efeb8f158690 | |
| ToppCell | CV-Severe-7|CV / Virus stimulation, Condition and Cluster | 3.58e-04 | 176 | 85 | 4 | 3de0c7d77210049e5616db21eed1490a17a5ec2d | |
| ToppCell | saliva-Severe-critical_progression_d12-22_with-steroid-Myeloid-Dendritic-conventional_dendritic_cell-DC_c2-CD1C|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k) | 3.58e-04 | 176 | 85 | 4 | 4aee9fdada077db7e531684ab938153f84dc8146 | |
| ToppCell | COVID-19-kidney-PCT-S3-2|COVID-19 / Disease (COVID-19 only), tissue and cell type | 3.58e-04 | 176 | 85 | 4 | b6497324e3e52f514ce556a3fa0c3011c45dcc7b | |
| ToppCell | LPS-antiTNF-Lymphocytic_NKT-T_cells-T-cells|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 3.58e-04 | 176 | 85 | 4 | bfbab3c5b738b3b0b1540f2059d0245fbd8c0031 | |
| ToppCell | facs-Trachea-18m-Mesenchymal-myofibroblast-tracheobronchial_smooth_muscle_cell-smooth_muscle_cell_of_trachea_l39|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 3.66e-04 | 177 | 85 | 4 | 928118b0ed120ec01c7d753ce523ab609ac24e5f | |
| ToppCell | 3'-GW_trimst-1.5-LargeIntestine-Neuronal-Glial_immature-Glia_3_(BCAN+)|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 3.66e-04 | 177 | 85 | 4 | d05497d2c80a66ec6a4e1733fea3a5534877a6a7 | |
| ToppCell | LPS-IL1RA+antiTNF-Lymphocytic_NKT|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 3.66e-04 | 177 | 85 | 4 | f1efd9c3074d5635700fe7fbebf3dd0b1e0a84f1 | |
| ToppCell | droplet-Marrow-nan-24m-Lymphocytic-naive_B_cell|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.74e-04 | 178 | 85 | 4 | cc0382b0ee1e6c76522e2c86ad1425c45debab5d | |
| ToppCell | Children_(3_yrs)|World / Lineage, Cell type, age group and donor | 3.74e-04 | 178 | 85 | 4 | df2ecd3214590b914f2762db57efe780ba038db3 | |
| ToppCell | Control-Lymphocytic_NKT-T_cells-T-cells|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 3.74e-04 | 178 | 85 | 4 | 910f8bea19d335455aba24e6a07b4834b709db5d | |
| ToppCell | droplet-Heart-HEART_(ALL_MINUS_AORTA)-30m-Mesenchymal-nan|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.82e-04 | 179 | 85 | 4 | e880c507f11ce75d104593a4ca29f0295f8125e8 | |
| ToppCell | cellseq-Epithelial-Epithelial_Glandular-Mucous-Mucous|cellseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 3.82e-04 | 179 | 85 | 4 | dc4d1b3f63df2c657fea51da011488ee724ee1bf | |
| ToppCell | Control-Lymphocytic_NKT-T_cells|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 3.82e-04 | 179 | 85 | 4 | d892d9496f1c33e23312092591eb2e968e736f7d | |
| ToppCell | 368C-Lymphocytic-CD8+_Cytotoxic_T-cell-CD8+_Cytotoxic_T_cell_3|368C / Donor, Lineage, Cell class and subclass (all cells) | 3.82e-04 | 179 | 85 | 4 | 10c7d371937d9d93c12c8d3465430ef9e0c2ec81 | |
| ToppCell | cellseq-Epithelial-Epithelial_Glandular-Mucous|cellseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 3.82e-04 | 179 | 85 | 4 | 9caa7903950c806921b1036103ad0d332a441253 | |
| Computational | Neighborhood of CDKN1C | 1.40e-05 | 27 | 60 | 4 | GNF2_CDKN1C | |
| Computational | Neighborhood of EGFR | 2.81e-05 | 32 | 60 | 4 | GNF2_EGFR | |
| Computational | Neighborhood of IGFBP1 | 4.04e-05 | 35 | 60 | 4 | GNF2_IGFBP1 | |
| Computational | Neighborhood of MMP11 | 8.38e-05 | 42 | 60 | 4 | GNF2_MMP11 | |
| Computational | Neighborhood of TIMP2 | 1.20e-04 | 46 | 60 | 4 | GNF2_TIMP2 | |
| Computational | Neighborhood of KISS1 | 1.54e-04 | 49 | 60 | 4 | GNF2_KISS1 | |
| Drug | AC1L1IPV | 5.22e-07 | 43 | 84 | 5 | CID000004683 | |
| Drug | pP-8 | 5.71e-06 | 10 | 84 | 3 | CID000444681 | |
| Drug | Pindolol [13523-86-9]; Up 200; 16.2uM; MCF7; HT_HG-U133A | 8.42e-06 | 197 | 84 | 7 | 2238_UP | |
| Drug | 2-Chloropyrazine [14508-49-7]; Up 200; 35uM; PC3; HT_HG-U133A | 8.42e-06 | 197 | 84 | 7 | 5750_UP | |
| Drug | Famprofazone [22881-35-2]; Up 200; 10.6uM; MCF7; HT_HG-U133A | 8.70e-06 | 198 | 84 | 7 | 3928_UP | |
| Drug | 1,2-dehydro-N-acetyldopamine | 1.35e-05 | 2 | 84 | 2 | CID006439639 | |
| Disease | CHARGE syndrome (implicated_via_orthology) | 2.23e-09 | 7 | 85 | 4 | DOID:0050834 (implicated_via_orthology) | |
| Disease | cD177 antigen measurement | 1.90e-07 | 18 | 85 | 4 | EFO_0021866 | |
| Disease | chylomicron measurement, very low density lipoprotein cholesterol measurement, phospholipids:total lipids ratio | 2.95e-05 | 61 | 85 | 4 | EFO_0008317, EFO_0008596, EFO_0020946 | |
| Disease | congenital heart disease (implicated_via_orthology) | 4.81e-05 | 69 | 85 | 4 | DOID:1682 (implicated_via_orthology) | |
| Disease | autism spectrum disorder (implicated_via_orthology) | 7.99e-05 | 152 | 85 | 5 | DOID:0060041 (implicated_via_orthology) | |
| Disease | basophil percentage of granulocytes | 9.91e-05 | 83 | 85 | 4 | EFO_0007995 | |
| Disease | very low density lipoprotein cholesterol measurement, cholesteryl esters:total lipids ratio | 1.17e-04 | 264 | 85 | 6 | EFO_0008317, EFO_0020944 | |
| Disease | Intellectual Disability | 3.12e-04 | 447 | 85 | 7 | C3714756 | |
| Disease | cholesterol in medium LDL measurement | 3.86e-04 | 49 | 85 | 3 | EFO_0022224 | |
| Disease | free cholesterol measurement, very low density lipoprotein cholesterol measurement | 4.01e-04 | 215 | 85 | 5 | EFO_0008317, EFO_0008591 | |
| Disease | Macrocephaly | 4.44e-04 | 11 | 85 | 2 | C0221355 | |
| Disease | phospholipids in medium VLDL measurement | 4.60e-04 | 52 | 85 | 3 | EFO_0022154 | |
| Disease | total lipids in medium LDL | 4.60e-04 | 52 | 85 | 3 | EFO_0022180 | |
| Disease | total cholesterol measurement, very low density lipoprotein cholesterol measurement | 4.83e-04 | 224 | 85 | 5 | EFO_0004574, EFO_0008317 | |
| Disease | Gastrointestinal Diseases | 5.31e-04 | 12 | 85 | 2 | C0017178 | |
| Disease | Functional Gastrointestinal Disorders | 5.31e-04 | 12 | 85 | 2 | C0559031 | |
| Disease | Cholera Infantum | 5.31e-04 | 12 | 85 | 2 | C1565321 | |
| Disease | apolipoprotein B measurement | 6.56e-04 | 663 | 85 | 8 | EFO_0004615 | |
| Disease | phospholipids in small VLDL measurement | 7.01e-04 | 60 | 85 | 3 | EFO_0022146 | |
| Disease | cholesterol:total lipids ratio, low density lipoprotein cholesterol measurement | 8.11e-04 | 144 | 85 | 4 | EFO_0004611, EFO_0020943 | |
| Disease | very low density lipoprotein cholesterol measurement | 9.44e-04 | 260 | 85 | 5 | EFO_0008317 | |
| Disease | fibrinogen measurement, coronary artery disease | 1.04e-03 | 154 | 85 | 4 | EFO_0001645, EFO_0004623 | |
| Disease | non-high density lipoprotein cholesterol measurement | 1.05e-03 | 713 | 85 | 8 | EFO_0005689 | |
| Disease | ankylosing spondylitis (is_implicated_in) | 1.36e-03 | 19 | 85 | 2 | DOID:7147 (is_implicated_in) | |
| Disease | energy expenditure measurement | 1.51e-03 | 20 | 85 | 2 | EFO_0008005 | |
| Disease | age at menopause | 1.83e-03 | 302 | 85 | 5 | EFO_0004704 | |
| Disease | free cholesterol:total lipids ratio, high density lipoprotein cholesterol measurement | 1.85e-03 | 303 | 85 | 5 | EFO_0004612, EFO_0020945 | |
| Disease | severe acute respiratory syndrome, COVID-19 | 1.87e-03 | 447 | 85 | 6 | EFO_0000694, MONDO_0100096 | |
| Disease | Immunologic Deficiency Syndromes | 1.99e-03 | 23 | 85 | 2 | C0021051 | |
| Disease | macula measurement | 2.20e-03 | 189 | 85 | 4 | EFO_0008375 | |
| Disease | Kallmann Syndrome | 2.55e-03 | 26 | 85 | 2 | C0162809 | |
| Disease | brain cancer (implicated_via_orthology) | 2.55e-03 | 26 | 85 | 2 | DOID:1319 (implicated_via_orthology) | |
| Disease | chylomicron measurement, very low density lipoprotein cholesterol measurement, lipid measurement | 2.64e-03 | 95 | 85 | 3 | EFO_0004529, EFO_0008317, EFO_0008596 | |
| Disease | low density lipoprotein cholesterol measurement, free cholesterol:total lipids ratio | 2.70e-03 | 200 | 85 | 4 | EFO_0004611, EFO_0020945 | |
| Disease | chylomicron measurement, triglyceride measurement, very low density lipoprotein cholesterol measurement | 2.72e-03 | 96 | 85 | 3 | EFO_0004530, EFO_0008317, EFO_0008596 | |
| Disease | Sezary Syndrome | 2.75e-03 | 27 | 85 | 2 | C0036920 | |
| Disease | chronic obstructive pulmonary disease (is_marker_for) | 2.80e-03 | 97 | 85 | 3 | DOID:3083 (is_marker_for) |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| WCSLPYEDSTWELKE | 751 | Q9HCK8 | |
| AWSYIFLPEEAWCDL | 3196 | Q9NR09 | |
| CETEAYWKELREHVW | 311 | Q9BWW8 | |
| WAESKPGAEYRWTLE | 376 | Q6UY09 | |
| DKVCWLRLDTYFIWS | 996 | Q9HAR2 | |
| KPVSREDQCSYKWWQ | 211 | Q96SW2 | |
| RTDCFESYKWTDIWA | 386 | P37023 | |
| RSPDEWSKLSSWFVC | 431 | P23109 | |
| SSDEAAYIWKVSTPW | 336 | Q9NZJ0 | |
| WVSRWASLADSYSDP | 661 | Q9Y4F5 | |
| WNETWYLKTIDICHD | 286 | Q9UBM7 | |
| VKWCSLPYEDSTWER | 906 | Q9P2D1 | |
| WSWSNCSRKYVTEFL | 441 | P59510 | |
| KSFPISWDTYWDRND | 326 | Q6UXT9 | |
| RCQWTEWFDEDYPKS | 1506 | Q9HC84 | |
| AWCWASYLEEEKAVA | 231 | Q96JM7 | |
| WNTVCDSEWYPSEAK | 286 | P30203 | |
| RSYPLYSCWEAWPEK | 196 | Q9GZQ6 | |
| WIERWGKLYEEESPS | 591 | P42898 | |
| TWRSWADPKVCCDYS | 116 | Q14117 | |
| EPEILWYKECRTKTW | 176 | Q9NZN1 | |
| WYKECRTKTWRPSIV | 181 | Q9NZN1 | |
| ATGEKKECWSWESYL | 266 | Q9Y468 | |
| SRLQYPDTWCFIDWT | 161 | P35408 | |
| SYKPDLIWSDGEWEC | 221 | P04066 | |
| SPSAWYSWCSQRLVE | 216 | P54098 | |
| LWCATTQDYGKDERW | 211 | Q9UBG0 | |
| DRWYEVLQFCWLSPE | 381 | Q8IWU2 | |
| FWCSRVEWSPREEKY | 406 | Q32M88 | |
| RPWCYVVKDSALSWE | 346 | Q04756 | |
| RLSDDCWEKITAWIY | 51 | Q15546 | |
| SWIDDYFDWVKPQSS | 941 | O15118 | |
| CWSALWDYETPKVIV | 21 | Q9UBL9 | |
| SPSKDDDTVWLTYWV | 76 | Q96HR9 | |
| WPDSYSNRVDCTWLI | 1996 | O60494 | |
| LYTWRAEEWQECTKT | 1556 | Q9P2N4 | |
| YLVKWCSLPYEDSTW | 796 | Q3L8U1 | |
| CREAGLWSEWSQPIY | 316 | Q01344 | |
| WWASSKKTECPECRE | 61 | Q9NZS9 | |
| KWCSLPYEESTWELE | 401 | Q8TD26 | |
| VCKWTYSAEKGWDDS | 191 | Q96C11 | |
| VKWRDLPYDQSTWEE | 651 | Q12873 | |
| VYKPDWCEVREDWSV | 1136 | Q9P0X4 | |
| WCEVREDWSVYLFSP | 1141 | Q9P0X4 | |
| SLTWIEYWPRDTTCS | 1641 | P01031 | |
| WVKDTYSPDEHLWAT | 321 | O95395 | |
| WSTDWSPYADQSIKV | 606 | Q9BYF1 | |
| DPRSCKVSWDWKDPY | 56 | O15033 | |
| ISSCTIDWYERWPEE | 2161 | Q0VDD8 | |
| WRPQIYRKCTDTAWL | 21 | Q8N4M1 | |
| AGYEETPLKCIWDWV | 251 | O95620 | |
| IIWSCDWSPDSKYFF | 671 | Q6IA86 | |
| ISGCTIDWFSRWPKD | 3106 | Q8TE73 | |
| TCEPKSENYTYIWWL | 261 | P11464 | |
| QSDSLWLVEFYAPWC | 41 | Q15084 | |
| TCEPKSENYTYIWWL | 261 | Q16557 | |
| WSRWKIYGTTDNLCS | 136 | P22897 | |
| WLWCGTTTDYDTDKL | 191 | P22897 | |
| DEDRYTTCWPKTWLA | 426 | Q96JX3 | |
| AVTDLYWCSWIATDL | 221 | Q9BXQ6 | |
| SWVTPESCLYKESWL | 621 | Q13576 | |
| TCEPKSENYTYIWWL | 261 | Q9UQ74 | |
| TCEPKSENYTYIWWL | 261 | Q00887 | |
| TPDEWWRVTQSYARS | 2306 | Q96Q15 | |
| EELEESRQKCPPWWY | 701 | Q15858 | |
| PLSTLSNWAYEFDKW | 811 | P51532 | |
| PSWCDRILWKSYPET | 686 | O15357 | |
| DPIWDLYCWREAATT | 301 | Q6ZUB1 | |
| SLLSWYDQEKRDLPW | 96 | Q9UIF7 | |
| AYWEEEPAEVRRCTW | 331 | Q9Y6Y8 | |
| IVWPVSYTRRDECKW | 91 | Q14563 | |
| TCEPKSENYTYIWWL | 261 | Q13046 | |
| AWRHYKTTPEADDWS | 376 | Q15120 | |
| RDAPCLLKTKDWWTY | 106 | Q13438 | |
| KWTECLWGIDPVSYE | 301 | Q9H1P3 | |
| RKAVTLNCLYETSWW | 36 | A0A1B0GX56 | |
| PSYRNRTASSWEEDW | 366 | Q9NRB3 | |
| EWFRSSWTYKDDPCQ | 266 | Q96S66 | |
| STWIIWCYECDEKLS | 121 | Q70EL2 | |
| DWDKAWDVTVRTCAY | 361 | P11217 | |
| YVEDSEESSSEWPWR | 391 | Q8WYR1 | |
| FTIPYWDWRDAEKCD | 231 | P14679 | |
| SCWAPNISEITYSWR | 151 | Q9P0V8 | |
| SAKSGRWLDETTYEW | 76 | Q9BQI6 | |
| TDWQEWVPSRCRLYS | 386 | O15482 | |
| EWWSGTECTIFTDPR | 66 | Q9NRZ5 | |
| QQCPRYSWRTSEWKE | 396 | Q9C0I4 | |
| YSWRTSEWKECQVSL | 401 | Q9C0I4 | |
| GPCAKSWFLTEWSER | 791 | Q6ZMP0 | |
| LCWPSVYWTERFLED | 166 | Q9P2T0 |